Anemia as a risk factor for chronic kidney disease

Kidney International

Volumn 72, Issue SUPPL. 107, 2007, Pages

  Iseki, K ^a   Kohagura, K ^a  

^a UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

Anemia; Chronic kidney disease (CKD); End stage renal disease (ESRD); Erthyropoiesis stimulating agent (ESA)

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIESIS STIMULATING AGENT; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANEMIA; CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; CONGESTIVE HEART FAILURE; DISEASE COURSE; DISEASE MARKER; EARLY INTERVENTION; ERYTHROPOIESIS; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPOXIA; INFECTION; KIDNEY BLOOD FLOW; KIDNEY FAILURE; LIFESTYLE; MORBIDITY; MORTALITY; NEPHROLOGIST; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SURVIVAL;

EID: 35348994919     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5002481     Document Type: Article

References (72)

1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13: S37-S40.
2. Nakai S, Shinzato T, Nagura Y et al. Patient registration committee, Japanese society for dialysis therapy. An overview of regular dialysis treatment in Japan (as of 31 December 2001). Ther Apher Dial 2004; 8: 3-32.
3. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease. A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
4. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events and hospitalization. N Engl J Med 2004; 351: 1296-1305.
5. Ninomiya T, Kiyohara Y, Kubo M et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005; 69: 228-236.
6. Irie F, Iso H, Sairenchi T et al. The relationship of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69: 1264-1271.
7. Tanaka T, Miyata T, Inagi R et al. Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways. Kidney Int 2003; 64: 2020-2032.
8. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
9. Kuriyama S, Tomonari H, Yoshida H. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
10. Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
11. Mohanram A, Zhahnaz ZZ, Shahinfar S et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66: 1131-1138.
12. Horwich TB, Fonarow GC, Hamilton MA et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Col Cardiol 2002; 39: 1780-1786.
13. Silverberg J, Racine N, Barre P, Sniderman AD. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4.
14. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
15. Singh AK, Szczech L, Tang KL et al. Correction of anemia with Epoetin Alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
16. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
17. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
18. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification and stratification. Am J Kidney Dis 2002; 39(Suppl 1): S170-S212.
19. Levey AS, Greens T, Kusek JW et al. A simplified equation to predict glomerular filtration rate from serum creatinine (abstract). J Am Soc Nephrol 2000; 11: 155A.
20. Imai E, Horio M, Nitta K et al. Estimation of glomerular filtration rate by the MDRD equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
21. Imai E, Horio M, Iseki K et al. Prevalence of chronic kidney disease (CKD) in Japanese general population predicted by MDRD equation modified by a Japanese coefficient. CEN 2007; 11: 156-163.
22. Astor BC, Muntner P, Levin A et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002; 162: 1401-1408.
23. National Kidney Foundation Kidney Early Evaluation Program. Anemia and chronic kidney disease. 6 A m J Kidney Dis 2005; 45(Suppl 2): S71-S80.
24. Lederer E, Ouseph R. Core curriculum in nephrology. Chronic kidney disease. Am J Kidney Dis 2007; 49: 162-171.
25. Iseki K, Ikemiya Y, Fukiyama K et al. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996; 49: 800-805.
26. Tozawa M, Iseki K, Iseki C et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41: 1341-1345.
27. Iseki K, Ikemiya Y, Iseki C, Takishita S. Hematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003; 18: 899-905.
28. Kohagura K, Yoshi S, Ishida A et al. Anemia as a risk factor of developing chronic kidney disease (CKD) in a large screened cohort. J Am Soc Nephrol 2006; 17: 339A.
29. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388.
30. Strippoli GFM, Tognoni G, Navaneethan SD et al. Haemoglobin targets: we were wrong, tome to move on. Editorial comment. Lancet 2007; 369: 346-350.
31. Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the anemia correction in diabetes (ACCORD) study. Am J Kidney Dis 2007; 49: 194-207.
32. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
33. Rossert J, Froissart M. Role of anemia in progression of chronic kidney disease. Semin Nephrol 2006; 26: 283-289.
34. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation and intrinsic renal disease. New Engl J Med 1982; 307: 652-659.
35. Krikken JA, Lely AT, Bakker SJL, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71: 260-265.
36. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
37. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174.
38. Abramson JL, Jurkovitz CT, Vaccarino V et al. Chronic kidney disease, anemia and incident stroke in a middle-aged, community-based population: The ARIC Study. Kidney Int 2003; 64: 610-615.
39. Iseki K, Fukiyama K. Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 1996; 50: 1672-1675.
40. Toyoda K, Fujii K, Fujimi S et al. Stroke in patients on maintenance hemodialysis: a 22-year single-center study. Am J Kidney Dis 2005; 45: 1058-1066.
41. Hirakata H, Kanai H, Fukuda K et al. Optimal hematocrit for the maximum oxygen delivery to the brain with recombinant human erythropoietin in hemodialysis patients. Clin Nephrol 2000; 53: 354-361.
42. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. JAMA 1994; 272: 205-211.
43. McCurry J. Japan battles with obesity. Lancet 2007; 369: 451-452.
44. Spangler JG, Konen JC. Hypertension, hyperlipidemia and abdominal obesity and the development of microalbuminuria in patients with non-insulin-dependent diabetes mellitus. J Am Board Fam Pract 1996; 9: 1-6.
45. Reid M, Bennett F, Wilks R, Forrester T. Microalbuminuria, renal function and waist: hip ratio in black hypertensive jamaicans. J Hum Hypertens 1998; 12: 221-227.
46. Metcalf P, Baker J, Scott A et al. Albuminuria in people at least 40 years old: effect of obesity, hypertension, and hyperlipidemia. Clin Chem 1992; 38: 1802-1808.
47. Tozawa M, Iseki K, Iseki C et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956-962.
48. Iseki K, Ikemiya Y, Kinjo K et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004; 65: 1870-1876.
49. Hsu CY, McCulloch CE, Iribarren C, Darbinian J. Go AS: body mass index and risk for end-stage renal disease. Ann Int Med 2006; 144: 21-28.
50. Domrongkitchaiporn S, Sritara P, Kitiyakara C et al. Risk factors for development of decreased kidney function in a southeast asian population: a 12-year cohort study. J Am Soc Nephrol 2005; 16: 791-799.
51. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: A population health perspective. Am J Resp Crit Care Med 2002; 165: 1217-1239.
52. Duran J, Esnaola S, Rubio R, Iztueta A. Obstructive sleep apnea-hypopnea and related clinical features in a population-based sample of subjects aged 30 to 70 years. Am J Resp Crit Care Med 2001; 163: 685-689.
53. Yaggi HK, Concato J, Kernan WN et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353: 2034-2041.
54. Hui DSC, Wong TYH, Ko FWS et al. Prevalence of sleep disturbances in Chinese patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 36: 783-788.
55. Fletcher EC. Obstructive sleep apnea and the kidney. J Am Soc Nephrol 1993; 4: 1111-1121.
56. Simmons D, Williams DRR, Powell MJ. Prevalence of diabetes in a predominantly Asian community: preliminary findings of the coventry diabetes study. Br Med J 1989; 298: 18-21.
57. Samanta A, Burden AC, Jagger C. A comparison of the clinical features and vascular complications of diabetes between migrant Asians and Caucasians in Leicester, UK. Diabetes Res Clin Pract 1991; 14: 205-214.
58. Ramirez SP, McClellan W, Port FK, Hsu SIH. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol 2002; 13: 1907-19172.
59. Yamagata K, Ishida K, Sairenchi T et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007; 71: 159-166.
60. Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 3640-4635.
61. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000; 97: 10526-10531.
62. Baqhlmann FH, Song R, Boehm SM et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
63. Agarwal R. Hypertension and survival in chronic hemodialysis patients - past lessons and future opportunities. Kidney Int 2005; 67: 1-13.
64. Parving H-H, Hovind P, Rossing K, Andersen S. Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 2001; 10: 515-522.
65. Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrology 2007; 3: 20-30.
66. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3): S1-S146.
67. Remuzzi G, Ingelfinger JR. Correction of anemia - payoffs and problems. N Engl J Med 2006; 355: 2144-2146.
68. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 2007; 356: 959-961.
69. Gejyo F, Saito A, Akizawa T et al. Japanese society for dialysis therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004; 8: 443-459.
70. Steinbrook R. Haemoglobin concentrations in chronic kidney disease. Lancet 2006; 368: 2101-2193.
71. Karter AJ, Ferrara A, Liu JY et al. Ethnic disparities in diabetic complications in an insured population. JAMA 2002; 287: 2519-2527.
72. Rossert J, Levin A, Roger SD et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47: 738-750.